Inclusion Criteria:  Is between 18 and 65 years of age inclusive; Has at least one discrete deep second degree (II°B) thermal burn injury (≤ 30% Total Body Surface Area (TBSA)) that requires surgical or enzymatic debridement and split thickness skin grafting (STSF) on any body surface excluding the face, joints, perineum and hands; Agrees to abstain from any other surgical treatment of the wound(s) for the duration of the study unless determined by the Principal Investigator to be medically necessary; Treatment with CellMist™ occurs with 7 days of burn injury; Demonstrates (as determined by the Principal Investigator) the ability and willingness to follow the requirements of the protocol; Understand the full nature and purpose of the study and provides voluntary written informed consent -  Exclusion Criteria:  Is pregnant or does not agree to use acceptable contraception methods for the duration of their participation in the clinical trial (latter applies to women and men of child bearing potential); Is breast feeding; Has a pre-existing local and/or systemic bacterial infection that requires antibiotic treatment for more than 2 days prior to study treatment; Demonstrates an anesthesia risk that (as determined by the Principal Investigator) prohibits treatment Body Mass Index (BMI) ≥ 39; The burn(s) at the target treatment area(s) results from chemical, electrical or radiation exposure; Has full thickness (III°) burns TBSA ≥ 20% Has comorbidities and/or medications and/or health status that (as determined by the Principal Investigator) could result in poor cell isolation and/or poor wound healing (e.g., uncontrolled and/or significant diabetes (≥8% HbA1c by medical record), peripheral vascular disease, active malignancy or treatment (other than surgery) of malignancy within the past 3 months, autoimmune disease, renal failure (glomerular filtration rate <60mL/minute) and/or systemic steroid usage); Known hypersensitivities to trypsin, collagenase, or GentLyase (dispase); Has a medical condition that would make life expectancy < 12 months; Is currently participating in another prospective investigational clinical trial; Does not agree to abstain from enrolling in any other study for the duration of this study; Gram staining of SkinGun™ cell suspension output shows excessive microbial bioburden (≥ 200 microbial particles/field)